Abstract: The present invention relates to compounds of formula (I): for use as peripheral NMDA receptor antagonists.

Abstract: The present invention relates to humanized antibodies that specifically bind to human BTN3A and their use in treating cancer and infectious disorders.

Abstract: The present invention relates to an asymmetric flow field-flow fractionation device (1) configured to separate a sample (8) of particles (12) dispersed in a liquid mobile phase (11), the device including a fractionation microchannel (2) comprising a sample inlet, a sample outlet, an auxiliary microchannel (3) comprising an auxiliary outlet, a semipermeable membrane (10) separating the fractionation microchannel (2) and the auxiliary microchannel (3), said membrane being permeable to liquid and being configured to maintain the particles (12) in said fractionation microchannel (2), the fractionation microchannel (2) being superimposed on the auxiliary microchannel (3), wherein the device (1) comprises two layers (19), each layer being with a microfabricated recess (14) which thickness (t) is less than 100IJm, the membrane (10) being mechanically held in between the two layers (19), the recesses (14) respectively defining the fractionation microchannel (2) and the auxiliary microchannel (3) on each side of the m

Abstract: A chimeric antigen receptor including: a binding domain, the full DAP 10 protein, the full DAP 12 protein, or a functional variant thereof, and a hook binding domain. Also, a vector system comprising one or more vector including: a nucleic acid comprising a nucleic acid sequence encoding a chimeric antigen receptor and optionally a nucleic acid encoding a hook fusion protein, preferably having a streptavidin core; wherein the nucleic acids are located on the same or on different vectors. Further, a lentiviral vector particles system, host cell and kit including the nucleic acids or vector system, and their use as a medicament, notably for immunotherapy.

Abstract: Positive electrodes based on organic active material, including molecules of thianthrene as the active material, substituted at specific positions. The electrodes have electrochemical properties enabling their use in a battery, in particular a recyclable battery. The electrodes thus replace the electrodes based on mineral salts that are conventionally used in batteries.

Abstract: A system for characterizing a pulse of electromagnetic radiation by time-resolved optical gating, which includes an interference-forming device which is adapted for superimposing four parts of the pulse. The system also includes a matrix image sensor which selectively captures, based on two-photon absorptions, an interference pattern formed by the pulse. The system allows obtaining the pulse shape completely and accurately, and is particularly suitable for characterizing ultrashort pulses. Also, the two-photon absorption can be produced in the matrix image sensor, or replaced by optical frequency doubling which is produced by an SHG crystal plate.

Abstract: An imaging method including: a) acquiring N successive positron emission tomography (PET) low resolution images ?i and simultaneously, N successive Ultrafast Ultrasound Imaging (UUI) images Ui of a moving object; b) determining from each UUI image Ui, the motion vector fields Mi that corresponds to the spatio-temporal geometrical transformation of the motion of the object; c) obtaining a final estimated high resolution image H of the object by iterative determination of a high resolution image Hn+1 obtained by applying several correction iterations to a current estimated high resolution image Hn, n being the number of iterations, starting from an initial estimated high resolution image H1 of the object, each correction iteration including at least: i) warping the estimated high resolution image Hn using the motion vector fields Mi to determine a set of low resolution reference images Lni; ii) determining a differential image Di by difference between each PET image ?i and the corresponding low resolution re

Abstract: The present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt and/or solvate thereof, for use as a drug, especially as an antibiotic. The present invention also relates to a pharmaceutical composition comprising said compound of formula (I) and at least one pharmaceutically acceptable excipient. The present invention further concerns a method of preparation of a compound of formula (I?).

Abstract: The present invention relates to an in vitro method for preparing a composition comprising mesenchymal stem cells (MSCs) intended for treating ischemia-reperfusion injury, comprising: a) providing MSCs; b) cultivating MSCs in a culture medium comprising a PPAR?/? agonist; c) removing the culture medium and washing the MSCs; and d) collecting MSCs in a pharmaceutically acceptable carrier, wherein the pharmaceutically acceptable carrier does not contain a PPAR?/? agonist. It further relates to MSCs obtained using the method of the invention, as well as their use as a medicament, preferably in the treatment or prevention of ischemia-reperfusion injury, wherein the method of treatment or prevention does not comprise administering a PPAR?/? agonist to the subject.

Abstract: The present invention relates to a process for treating aqueous effluents from the primary circuit of a nuclear power plant implementing a separation of boric acid using a reverse osmosis membrane, characterized by the fact that it comprises steps consisting of treating the effluents using a multi-stage assembly composed of reverse osmosis modules comprising a membrane with a high boron rejection rate, arranged in parallel and in series, and recycling of the intermediate products to different points in the assembly.

Abstract: Disclosed is a method for fabricating an optical component that is configured so as to generate on an illumination target in the near-field an illumination that has a determined pattern according to which each point (i) of the illumination target receives a quantity of light (alpha i) via an illumination generated by an illumination light source that is incident on the optical component, which is placed between the illuminating light source and the illumination target.

Abstract: Monocytopoiesis is a hematological process that supplies the periphery with monocytes and subsequently with macrophages and monocyte-derived dendritic cells. Typically, monocytes circulate in the bloodstream for a very short time before undergoing apoptosis, however, stimulatory signals can trigger monocyte survival by inhibiting the apoptotic pathway, and thus contribute to the maintenance of the inflammatory response. Accordingly, there is a need for methods and pharmaceutical compositions for modulating monocytopoiesis. Now, the inventors show that type I interferons signaling promote the differentiation of monocyte-derived phagocytes at the level of their progenitors. Importantly, IFN-alpha and -beta were found to efficiently generate the development of monocyte-derived antigen-presenting cells while having no impact on the precursor activity of conventional dendritic cells. Accordingly, modulators of type I interferon (e.g.

Abstract: A method for determining a rate of sedimentation or of creaming of a mixture in suspension, including an application of a sample of the mixture in suspension to a photonic microresonator, an application of a first optical signal at the input of the photonic microresonator carrying the sample of the mixture in suspension, an acquisition and a recording of a second optical signal, delivered at the output of the microresonator carrying the sample of the mixture in suspension, and a determination of information representing a rate of sedimentation or of creaming of the mixture from the recorded second signal, by successive iterations of spectral analysis of the second optical signal.

Abstract: The invention is based on the discovery of a new bacterial compound with analgesic properties which could be used as a new tool for the treatment of pain disorders such as visceral pain. Studying the mechanisms implicated in analgesic properties of the probiotic Escherichia coli strain Nissle 1917 (EcN), inventors characterized, the amino fatty acids produced by EcN, which display the Ecn analgesic properties. One of these compounds inhibits the hypersensitivity to colorectal distension induced by capsaicin, which is a very powerful nociceptive compound and acts via the GABA B receptor. Furthermore, inventors demonstrate that this compound is able to cross the cellular epithelial barrier (such as the intestinal epithelium). Thus, the invention relates to a lipopetide compound, derived from gamma-aminobutyric acid. The invention also relates to a lipopeptide compound according to the invention for the treatment of treating pain disorder, such as somatic pain and visceral pain.

Abstract: The present invention relates the field of reducing CD95-mediated cell motility in a subject, in particular for their use in the reduction of CD-95 mediated cancer cell motility, the reduction of CD95-mediated lymphocyte motility and/or B cell maturation, or the treatment of B-cell tumors, in a subject. The inventors identified a novel family of compounds having the ability to disrupt CD95/PLC?1 interaction and to neutralize the CD95-mediated calcium signaling pathway and cell migration in human peripheral blood lymphocytes (PBLs) and Th17 cells.

Abstract: A method for preparing a nanoporous silica sol-gel matrix containing at least one amine reactant selected from hydroxylamine, methylhydroxylamine, tertbutylhydroxylamine, methoxyamine, tetraethylenepentamine, dicarboxylic acid dihydrazides, particularly adipic acid dihydrazide, and the salts thereof, said method including the following steps: a) synthesising a gel from tetramethoxysilane or from a mixture of tetramethoxysilane and another organosilicon precursor selected from among phenyltrimethoxysilane, phenyltriethoxysilane, a fluoroalkyltrimethoxysilane, a fluoroalkyltriethoxysilane, a chloroalkylmethoxysilane, a chloroalkylethoxysilane, an alkyltrimethoxysilane, an alkyltriethoxysilane, an aminopropyltriethoxysilane and the mixtures thereof, the synthesis being performed in an aqueous medium at a temperature ranging from 10 to 70° C.

Abstract: Described herein are anti-CD277 antibodies which: activates or inhibit the cytolytic function of V?9/V?2 T cells, and/or costimulates T cells together with CD3-TCR, and/or costimulates T cells in addition to CD28-B7 costimulation, and/or increases the activity and/or survival of monocytes and dendritic cells. The use of said antibodies in therapy is also described.

Abstract: The invention concerns a system for controlling the temperature of a microfluidic chip comprising a Peltier module (10) having a cold face (10a) and a hot face (10b) and connected to a power generator (11), a thermal regulation device (12) having a thermal regulated face (12a) applied against one of the faces of the Peltier module, at least one temperature sensor (17) being applied on the other face of the Peltier module and being intended to be applied against one of the main faces of a microfluidic chip and control means (18) configured to control the power generator (11) of the Peltier module depending on a temperature of the face of the Peltier module provided with said at least one temperature sensor and at least one temperature setting information selected from a target temperature and a target temporal temperature profile to regulate a temperature of the face of the Peltier module to said temperature setting information.

Abstract: A method for preparing a monolithic nanoporous silicate sol-gel material for modulating the pore size distribution for one single starting composition without the addition of a structuring agent. The method includes the following steps: a) synthesising a gel from at least one organosilylated precursor, the synthesis being carried out in an aqueous medium, optionally including an organic solvent and without a structuring agent, and b) drying the gel obtained in step a) at a temperature between 10° C. and 70° C., preferably between 15° C. and 55° C. and more preferably between 20° C. and 40° C., in a gas flow in a drying chamber to obtain a monolithic nanoporous silicate sol-gel material and a residual relative humidity in the drying chamber of between 0.1 and 20%, preferably between 0.5 and 10% and more preferably about 5%.

Abstract: The present invention relates to antibodies having specificity to Nectin-4 and uses thereof.